Articles related to BREAST SURGERY

Dr. Rita Rao shares her expert perspective on the goals of neoadjuvant therapy, treatment selection, and the evolving landscape of HER2-targeted strategies.

The combination of imlunestrant plus abemaciclib demonstrated significant progression-free survival benefit across all subgroups, including patients with prior CDK4/6 inhibitor use and those with visceral metastases.

In a cohort of 601 women aged ≥65 years with low-risk breast cancer treated without radiotherapy, the 10-year local recurrence rate was 5.5%, with only 0.5% breast cancer-specific mortality.

Breast cancer surgical management requires ongoing patient education to address persistent misconceptions about treatment options and outcomes.

The recent FDA approval of Lumicell’s breast cancer imaging system introduces a novel intraoperative tool that significantly enhances the precision of tumor resections, potentially reducing the need for subsequent corrective surgeries.

With expert-led sessions encompassing a broad spectrum of breast disease management, from genetic risk assessment to cutting-edge oncological treatments, the course is a great opportunity to fortify your practice and enhance patient care.